CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Lenvatinib plus Pembrolizumabdrug
Likely dose
Lenvatinib plus Pembrolizumab 12mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03895970
NCT03895970Phase 2Completed
CompareCT.gov

Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical Study

Peking Union Medical College Hospital·interventional·Posted Mar 29, 2019·Updated Mar 29, 2023

In Brief

A Phase 2 clinical trial evaluating Lenvatinib plus Pembrolizumab for Liver Neoplasm Malignant Primary and 3 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The investigators design a phase IIB clinical study to explore the efficacy and safety of lenvatinib plus pembrolizumab as a second-line treatment in patients with advanced hepatobiliary malignant tumors and to analyze potential biomarkers of therapeutic response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Neoplasm Malignant Primary, Cholangiocarcinoma, Combinational Immunotherapy, Biomarker
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 29, 2019
Enrollment StartApr 20, 2019
Primary CompletionApr 1, 2021
Study CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.3 years ago

Interventions

Lenvatinib plus Pembrolizumabdrug

Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.